BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The data presented at ELCC 2026 demonstrate the potential of BioNTech's late-stage lung cancer portfolio, with updates on Pumitamig and Gotistobart as well as first clinical data for HER3-targeted ADC candidate BNT326/YL202, driving forward differentiated treatment approaches for various lung cancer stages

  60% confidence

• BioNTech currently has 16 clinical trials running for various lung cancer subtypes and treatment lines, including four registrational Phase 3 trials and five trials with innovative combination approaches

  60% confidence

• Pumitamig data support the currently ongoing registrational Phase 3 trial ROSETTA Lung-01 for first-line treatment of extensive-stage small cell lung cancer

  60% confidence

• BioNTech's goal is to offer patients with lung cancer innovative treatment options that aim to enable significant long-term benefit across all disease stages

  60% confidence

• Gotistobart showed a clinically relevant overall survival benefit with a 54% reduction in mortality risk compared to current standard of care in second-line and later treatment of squamous lung cancer

  60% confidence

Data points we hold from this source